Novo Nordisk Invests $4.1B in New North Carolina Facility

  • Novo Nordisk to invest $4.1 billion in a new fill-finish manufacturing facility in Clayton, North Carolina.
  • The expansion will add 1,000 new jobs and 1.4 million square feet of production space.

Novo Nordisk has announced plans to invest $4.1 billion to build a second fill and finish manufacturing facility in Clayton, North Carolina. This expansion aims to increase production capacity for current and future injectable treatments for obesity and other serious chronic diseases.

The new facility will add 1.4 million square feet of production space dedicated to aseptic manufacturing and finished production processes. This will effectively double the combined square footage of Novo Nordisk’s existing facilities in North Carolina. The project will also create 1,000 new jobs, in addition to the nearly 2,500 employees the company already has in the region.

“It took us a century to reach 40 million patients, but through this expansion and continued investment in our global production, we’re building Novo Nordisk’s ability to serve millions more people living with serious chronic diseases in the future,” said Lars Fruergaard Jørgensen, president and CEO of Novo Nordisk. “This is yet another real signal of our efforts to scale up our production to meet the growing global need for our life-changing medicines and the patients of tomorrow.”

The new facility will be designed with state-of-the-art technology, including roof-top solar panels and innovative water strategies, to ensure efficient and environmentally sustainable operations.

Henrik Wulff, Executive Vice President, Product Supply, Quality & IT, added, “Clayton was the first manufacturing site for Novo Nordisk in the US, and this new, large-scale investment confirms the continued importance of our production facilities there as cornerstones of our company’s growth.”

Early clearing and foundational work for the 56-acre facility footprint are already underway. Construction is expected to be completed between 2027 and 2029, with around 2,000 external contractors involved at the peak of the project.

Experience the future of contract manufacturing

Join us at CDMO Live, 7-8 May 2025 in Rotterdam for an exclusive live event dedicated to contract manufacturing partnerships. Apply for your ticket.

Sign up to our free weekly newsletter for all the latest contract manufacturing news.  Register here

ELEARNING

Learn the essentials of successful biopharma outsourcing

New eLearning course distils 100+ expert interviews into 10 engaging modules.

tick Overview of outsourcing trends 
tick Expert insights and case studies 
tick Helpful resources and quizzes

Who do you rate?
Recommend a Supplier

Help us find the most innovative and trusted suppliers in Pharma and Biotech.